Kanghong Pharmaceutical (002773.SZ) subsidiary received the KHN923 injection drug clinical trial approval notice

Zhitongcaijing · 2d ago

Zhitong Finance App News, Kanghong Pharmaceutical (002773.SZ) issued an announcement. Recently, the company's subsidiary Chengdu Kanghong Biotechnology Co., Ltd. (“Kanghong Biology”) received the KHN923 injection “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. The drug's indication: Alzheimer's disease.

KHN923 injection is a bispecific antibody targeting beta-amyloid (Aβ) /transferrin receptor 1 (TFR1) developed by Kanghong Biology. It targets the transferrin receptor TFR1 through anti-TFR1 anthropogenic nanoantibodies, efficiently crosses the blood-brain barrier through endogenous receptor-mediated cytosis and selectively binds Aβ aggregates in different states; after binding to Aβ, active antibodies can be removed through TcgammaR and TFR1 mediated phagocytosis on microglia to achieve active anti-Aβ antibodies Blood-brain barrier and efficient transport ultimately achieve efficient removal of Aβ to delay Alzheimer's disease progress.